Did you develop cancer after prolonged exposure to glyphosate or Roundup® weed killer?
The History of the Roundup® Cancer Lawsuit
Monsanto, an agricultural biotechnology company now owned by Bayer AG, developed the herbicide Roundup® in the 1970s and placed it on the market in 1974. The active chemical in Roundup® is called glyphosate.
In 2015, the International Agency for Research on Cancer (IARC) issued a report relating to glyphosate. The IARC classified glyphosate as a Group 2A agent, which means that it is probably carcinogenic to humans. The IARC concluded that the cancers most associated with glyphosate exposure are non-Hodgkin lymphoma and its various subtypes.
Despite this assessment and report, Monsanto maintains to this day that Roundup® and glyphosate-based products do not pose a health hazard to humans. Monsanto’s statements are misleading and because they have aggressively promoted Roundup® as a safe product for decades, in spite of conflicting evidence, consumers who regularly come in contact with Roundup® may not be adhering to proper safety precautions when using the herbicide.
Farmers, landscapers, municipalities, and residential users, among others, have all relied on Roundup® to control weed overgrowth over the years. Monsanto’s patent to manufacture glyphosate expired in 2000 and since then, other companies have been able to manufacture and sell their own glyphosate-based products, further driving the increase in use and exposure.
Do I have a claim in the Roundup® lawsuit?
Generally, a potential client needs to have been diagnosed with a related cancer after two consecutive years of exposure, with a minimum of eight hours of exposure each year (or a minimum of 16 hours over two years).
Contact us and our attorneys will review your case.
Cancers potentially associated with Roundup®
- Non-Hodgkin’s Lymphoma (NHL) and its certain
- B- cell lymphomas
(about 85% of all NHLs in the U.S.)
- Diffuse large B-cell lymphoma (DLBCL) (about 33% of all NHLs in the U.S.)
- Follicular lymphoma (about 20% of all lymphomas in the U.S.)
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL)
- Burkitt Lymphoma
Lymphoma (Waldenström Macroglobulinemia)
- Hairy cell leukemia (HCL)
- Mantle cell lymphoma (about 5% of lymphomas)
- Marginal zone B-cell lymphomas (about 5–10% of all lymphomas)
- B-Lymphoblastic Lymphoma (LL)
- T-cell lymphomas
(about 15% of NHLs in the U.S.)
- Peripheral T cell lymphomas (PTCL)
- Large Granular Lymphocytic Leukemia (LGL)
- Anaplastic Large Cell Lymphoma (ALCL)
- B- cell lymphomas (about 85% of all NHLs in the U.S.)
What should I do?
If you were diagnosed with Non-Hodgkin Lymphoma or one of its subtypes listed above and have used Roundup®, you may have a legal claim for compensation. Contact our attorneys to discuss your specific legal issues.